AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...

AstraZeneca's breast cancer drug datopotamab deruxtecan didn't show a statistical significance in overall survival compared with chemotherapy, results showed at a phase three trial.

Arab Finance: AstraZeneca Egypt is planning to inject $50 million into new investments in Egypt, equivalent to nearly 50% of the company’s capital, the firm’s Country President Hatem Werdany stated.

U.S. stock futures are edging higher after the Federal Reserve's jumbo-sized interest-rate cut last week. Here's what investors need to know today. Intel (INTC) shares are jumping 4% in premarket ...